$CODX
Co-Diagnostics Inc Stock $codx

$codx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022072 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$5.094M	$5.023M	$22.70M
YoY Change	-83.08%	-81.64%	13.38%
Cost Of Revenue	$767.9K	$915.4K	$3.282M
YoY Change	-76.81%	-63.45%	0.37%
Gross Profit	$4.327M	$4.108M	$19.42M
YoY Change	-83.85%	-83.47%	15.92%
Gross Profit Margin	84.93%	81.78%	85.54%
Selling, General & Admin	$5.512M	$3.941M	$5.574M
YoY Change	-23.15%	-52.65%	34.97%
% of Gross Profit	127.4%	95.93%	28.71%
Research & Development	$5.037M	$3.890M	$3.771M
YoY Change	-14.52%	-16.69%	69.88%
% of Gross Profit	116.43%	94.69%	19.42%
Depreciation & Amortization	$313.0K	$423.8K	$247.3K
YoY Change	232.83%	516.78%	253.23%
% of Gross Profit	7.23%	10.32%	1.27%
Operating Expenses	$10.86M	$8.255M	$9.593M
YoY Change	-17.46%	-36.81%	49.42%
Operating Profit	-$6.536M	-$4.147M	$9.824M
YoY Change	-147.95%	-135.17%	-4.9%
Interest Expense	$169.1K	-$44.85K	-$9.950K
YoY Change	-415.8%	-132.24%	-97.79%
% of Operating Profit			-0.1%
Other Income/Expense, Net	$3.060M	$719.2K	$3.277M
YoY Change	-5812.95%	416.97%
Pretax Income	-$3.476M	-$3.428M	$13.10M
YoY Change	-125.6%	-128.73%	32.6%
Income Tax	-$2.115M	-$741.5K	$1.386M
% Of Pretax Income			10.58%
Net Earnings	-$1.361M	-$2.686M	$11.71M
YoY Change	-111.86%	-127.45%	48.31%
Net Earnings / Revenue	-26.72%	-53.48%	51.61%
Basic Earnings Per Share	-$0.04	-$0.08	$0.35
Diluted Earnings Per Share	-$0.04	-$0.08	$337.5K
COMMON SHARES
Basic Shares Outstanding	33.78M shares	32.47M shares	33.94M shares
Diluted Shares Outstanding	31.32M shares	32.47M shares	34.71M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.49M	$96.00M	$97.42M
YoY Change	3.08%	32.62%	62.13%
Cash & Equivalents	$81.51M	$86.05M	$97.42M
Short-Term Investments	$4.982M	$9.952M	$0.00
Other Short-Term Assets	$1.316M	$1.605M	$1.354M
YoY Change	171.31%	51.38%	88.0%
Inventory	$5.442M	$4.706M	$4.901M
Prepaid Expenses
Receivables	$7.962M	$12.26M	$21.66M
Other Receivables	$705.8K	$0.00	$0.00
Total Short-Term Assets	$101.9M	$114.6M	$125.3M
YoY Change	-0.36%	26.85%	58.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.438M	$2.421M	$2.858M
YoY Change	59.9%	102.98%	180.17%
Goodwill	$15.39M	$15.39M
YoY Change
Intangibles	$26.88M	$26.98M
YoY Change
Long-Term Investments	$748.7K	$877.1K	$983.6K
YoY Change	-27.6%	-31.27%	2.46%
Other Assets
YoY Change
Total Long-Term Assets	$45.93M	$46.27M	$45.81M
YoY Change	1395.23%	1774.11%	2202.16%
TOTAL ASSETS
Total Short-Term Assets	$101.9M	$114.6M	$125.3M
Total Long-Term Assets	$45.93M	$46.27M	$45.81M
Total Assets	$147.8M	$160.8M	$171.2M
YoY Change	40.32%	73.34%	110.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.056M	$848.4K	$1.215M
YoY Change	156.99%	98.62%	81.35%
Accrued Expenses	$1.512M	$1.819M	$2.897M
YoY Change	-27.52%	-55.55%	69.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.012M	$6.716M	$13.02M
YoY Change	45.93%	42.02%	202.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.086M	$4.343M	$4.548M
YoY Change	185.68%	446.61%	726.84%
Total Long-Term Liabilities	$6.883M	$9.654M	$4.548M
YoY Change	537.15%	1114.93%	726.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.012M	$6.716M	$13.02M
Total Long-Term Liabilities	$6.883M	$9.654M	$4.548M
Total Liabilities	$12.90M	$16.37M	$23.44M
YoY Change	147.98%	196.37%	382.24%
SHAREHOLDERS EQUITY
Retained Earnings	$61.84M	$63.20M
YoY Change
Common Stock	$34.33K	$34.31K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$12.99M	$2.599M
YoY Change
Treasury Stock Shares	3.414M shares	532.4K shares
Shareholders Equity	$134.9M	$144.5M	$147.7M
YoY Change
Total Liabilities & Shareholders Equity	$147.8M	$160.8M	$171.2M
YoY Change	40.32%	73.34%	110.99%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.361M	-$2.686M	$11.71M
YoY Change	-111.86%	-127.45%	48.31%
Depreciation, Depletion And Amortization	$313.0K	$423.8K	$247.3K
YoY Change	232.83%	516.78%	253.23%
Cash From Operating Activities	$1.118M	$1.654M	$7.806M
YoY Change	-90.28%	-86.68%	-36.38%
INVESTING ACTIVITIES
Capital Expenditures	-$230.0K	-$507.6K	-$396.6K
YoY Change	38.81%	109.75%	183.29%
Acquisitions
YoY Change
Other Investing Activities	$4.969M	-$9.952M	$1.255M
YoY Change	379.86%	-96250.24%	-50.38%
Cash From Investing Activities	$4.739M	-$10.46M	$858.7K
YoY Change	444.84%	4415.44%	-64.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.39M	-2.572M	150.0K
YoY Change	-189098.0%	-972.03%	0.0%
NET CHANGE
Cash From Operating Activities	1.118M	1.654M	7.806M
Cash From Investing Activities	4.739M	-10.46M	858.7K
Cash From Financing Activities	-10.39M	-2.572M	150.0K
Net Change In Cash	-4.537M	-11.38M	8.815M
YoY Change	-136.64%	-191.1%	-40.48%
FREE CASH FLOW
Cash From Operating Activities	$1.118M	$1.654M	$7.806M
Capital Expenditures	-$230.0K	-$507.6K	-$396.6K
Free Cash Flow	$1.348M	$2.162M	$8.202M
YoY Change	-88.45%	-82.93%	-33.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001692415
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021Q2	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
	CODX	Noncash Lease Expense NoncashLeaseExpense		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	CODX	Payments To Acquire Interest In Joint Ventures PaymentsToAcquireInterestInJointVentures		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2021Q4	us-gaap	Liabilities Liabilities	25559184	usd
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q2	CODX	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38148
	dei	Entity Registrant Name EntityRegistrantName	CO-DIAGNOSTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	UT
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2609396
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 S. Foothill Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite D
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84109
	dei	City Area Code CityAreaCode	(801)
	dei	Local Phone Number LocalPhoneNumber	438-1036
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	CODX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33780992	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86045405	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88607234	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9951550	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1255266	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12260009	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20839182	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4705921	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2004169	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1569374	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2338444	usd
CY2022Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	35200	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	114567459	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	115119295	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2421349	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1933216	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	530033	usd
CY2022Q2	us-gaap	Goodwill Goodwill	15388546	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14706818	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26981667	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27195000	usd
CY2022Q2	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	877089	usd
CY2021Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	1004953	usd
CY2022Q2	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	75000	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	75000	usd
CY2022Q2	us-gaap	Assets Assets	160841143	usd
CY2021Q4	us-gaap	Assets Assets	160034282	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	848379	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	607506	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1818773	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3859652	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	287900	usd
CY2022Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	3761084	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	5767304	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2213088	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	150000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6716136	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12597550	usd
CY2022Q2	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1464024	usd
CY2021Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1067853	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5310573	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7228444	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	201266	usd
CY2022Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2678204	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	4665337	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9654067	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12961634	usd
CY2022Q2	us-gaap	Liabilities Liabilities	16370203	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34313432	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33780992	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33819862	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33819862	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	34313	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	33820	usd
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	532440	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	-0	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2599478	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83838533	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80271999	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	63197572	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	54169279	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	144470940	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475098	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	160841143	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	160034282	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5023226	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27358140	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27722270	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47382909	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	915432	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	2504355	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4197383	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5776920	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	4107794	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	24853785	usd
	us-gaap	Gross Profit GrossProfit	23524887	usd
	us-gaap	Gross Profit GrossProfit	41605989	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1472225	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5853313	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4124373	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7050859	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	9785213	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2468421	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2468433	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5390616	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5404122	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3889844	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4669160	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7661171	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6886223	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	424342	usd
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	71714	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	671606	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	138719	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8254832	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	13062620	usd
	us-gaap	Operating Expenses OperatingExpenses	17847766	usd
	us-gaap	Operating Expenses OperatingExpenses	19479923	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4147038	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	11791165	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	5677121	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	22126066	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	61671	usd
CY2021Q2	us-gaap	Interest Income Other InterestIncomeOther	10529	usd
	us-gaap	Interest Income Other InterestIncomeOther	73064	usd
	us-gaap	Interest Income Other InterestIncomeOther	25186	usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-48740	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-142161	usd
CY2022Q2	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	812822	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	4192712	usd
CY2022Q2	CODX	Loss On Equity Method Investment In Joint Venture LossOnEquityMethodInvestmentInJointVenture	-106525	usd
CY2021Q2	CODX	Loss On Equity Method Investment In Joint Venture LossOnEquityMethodInvestmentInJointVenture	128595	usd
	CODX	Loss On Equity Method Investment In Joint Venture LossOnEquityMethodInvestmentInJointVenture	-127864	usd
	CODX	Loss On Equity Method Investment In Joint Venture LossOnEquityMethodInvestmentInJointVenture	-336348	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	719228	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	139124	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3995751	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-311162	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3427810	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11930289	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9672872	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21814904	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-741507	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2145076	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	644580	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4130716	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28794047	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32509664	shares
	us-gaap	Net Income Loss NetIncomeLoss	9028292	usd
	us-gaap	Net Income Loss NetIncomeLoss	17684188	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1255266	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.62
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32472251	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28728828	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32472251	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29741265	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33253612	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29833955	shares
	us-gaap	Net Income Loss NetIncomeLoss	9028292	usd
	us-gaap	Net Income Loss NetIncomeLoss	17684188	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	671105	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138719	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2908381	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2440347	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	4192712	usd
	CODX	Noncash Lease Expense NoncashLeaseExpense	13761	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-127864	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-336348	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-142161	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1917871	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	526781	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11404	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	147775	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8567769	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	766894	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-791954	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	670478	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2920658	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3874485	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-150000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-142173	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1918510	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-590380	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1702718	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1715383	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9460222	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	24694101	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	904160	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	381981	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	444899	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2561829	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2225771	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	778223	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9951550	usd
	CODX	Payments To Acquire Interest In Joint Ventures PaymentsToAcquireInterestInJointVentures	-314575	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9600444	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2158365	usd
	CODX	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	177871	usd
	CODX	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	444899	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2599478	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2421607	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27297365	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88607234	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42976713	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86045405	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	70274078	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4534330	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3423700	usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	218906	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	681327	usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments	681728	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475098	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50001	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1375097	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11714596	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	147714792	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27869	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1533284	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	480776	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2599478	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	144470940	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	66696509	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	148980	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1513012	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	7898975	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	76257476	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	295917	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	927337	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	9785213	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	87265943	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2004169	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	983088	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1021081	usd
CY2022Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	12941010	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	681001	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12260009	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	21508779	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	669597	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20839182	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4705921	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3927698	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3889844	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7661171	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4669160	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6886223	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zxsGYwdrzQSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zlEM3t37rM3h">Concentrations Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which are each responsible for generating <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zaSy5R5SbSb8" title="Concentration risk percentage"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z62jfSLcM77e" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the three and six months ended June 30, 2022. One customer accounted for approximately <span title="Concentration risk percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuvMHCCXlCng" title="Concentration risk percentage">55</span></span>% of total revenue for the three months ended June 30, 2022, and two customers together accounted for approximately <span title="Concentration risk percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVPANSmHaSd3">46</span></span>% of total revenue for the six months ended June 30, 2022. Two customers together accounted for approximately <span title="Concentration risk percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlns0Bh3Ggo" title="Concentration risk percentage">68</span></span>% of total revenue for the three months ended June 30, 2021, and three customers together accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziMSDT8hxI93" title="Concentration risk percentage"><span title="Concentration risk percentage">56</span></span>% of total revenue for the six months ended June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four customers accounted for more than <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zfdEaBf5GBLj" title="Concentration risk percentage">10</span>% of accounts receivable at June 30, 2022 and two customers accounted for more than <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zucjKlmwl8d5" title="Concentration risk percentage">10</span>% of accounts receivable at December 31, 2021. These customers together accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zXxPAySsXa4e" title="Concentration risk percentage">75</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zPXLgEGgeY18" title="Concentration risk percentage">66</span>% of accounts receivable at June, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	CODX	Remeasurement Of Acquisition Contingencies RemeasurementOfAcquisitionContingencies	78617	usd
CY2022Q1	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	64587	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14706818	usd
	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	681728	usd
CY2022Q2	us-gaap	Goodwill Goodwill	15388546	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	213333	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26981667	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27195000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10432641	usd
	CODX	Contingent Considered Issued For Measurement Period Adjustments ContingentConsideredIssuedForMeasurementPeriodAdjustments	199359	usd
	CODX	Contingent Considered Issued For Business Acquisitions ContingentConsideredIssuedForBusinessAcquisitions	-4192712	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	6439288	usd
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y6M
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5023226	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27358140	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27722270	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	47382909	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	150000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	150000	usd
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised	0.51
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	9785213	usd
	us-gaap	Net Income Loss NetIncomeLoss	9028292	usd
	us-gaap	Net Income Loss NetIncomeLoss	17684188	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32472251	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28794047	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32509664	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28728828	shares
CY2021Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	947218	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	743948	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1105127	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32472251	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29741265	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33253612	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29833955	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.62
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1391156	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1155136	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	931341	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	146133	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1111363	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.12
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.31
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M13D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	70791	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.10
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M20D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1040572	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.19
CY2022Q2	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable	1.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M20D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	526281	shares
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	8.15
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	4.01
CY2021	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P4Y8M12D
	CODX	Share Based Compensation Issued For Adjustments To Contingent Purchase Consideration ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration	8719	shares
	CODX	Issued For Adjustments To Contingent Purchase Consideration Period Weighted Average Exercise Price IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice	9.13
	CODX	Issued For Adjustments To Contingent Purchase Consideration Weighted Average Grant Date Fair Value IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue	1.88
	CODX	Issued For Adjustments To Contingent Purchase Consideration Weighted Average Remaining Contractual Term1 IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageRemainingContractualTerm1	P4Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	50000	shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	2.00
	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.22
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2022Q2	CODX	Share Based Compensation Arrangement By Share Based Payment Award Options Non Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice	8.81
CY2022Q2	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	2.43
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P4Y6M
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1533286	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	927337	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2908381	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.216	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	644580	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2440347	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-741507	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.067	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2145076	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4130716	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	84364	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	170951	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	88080	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	164160	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	172444	usd
	us-gaap	Lease Cost LeaseCost	335111	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	147566	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	303059	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50774	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	501399	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12233	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	489166	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	287900	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	201266	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	167445	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	321350	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031	pure
CY2022Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	293595	usd
CY2022Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	303059	usd
CY2022Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	50774	usd
CY2022Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	647428	usd
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	30000000.0	usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	-0	shares
	CODX	Repurchases Of Common Stock RepurchasesOfCommonStock	532440	shares
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	532440	shares

Files In Submission

Name	View Source	Status
0001493152-22-022072-index-headers.html	Edgar Link	pending
0001493152-22-022072-index.html	Edgar Link	pending
0001493152-22-022072.txt	Edgar Link	pending
0001493152-22-022072-xbrl.zip	Edgar Link	pending
codx-20220630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
codx-20220630_cal.xml	Edgar Link	unprocessable
codx-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
codx-20220630_lab.xml	Edgar Link	unprocessable
codx-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CODX
Co-Diagnostics Inc Stock $codx

2022 Q3 Form 10-Q Financial Statement

#000149315222022072 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX Co-Diagnostics Inc Stock $codx

2022 Q3 Form 10-Q Financial Statement

#000149315222022072 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX
Co-Diagnostics Inc Stock $codx